20.11.2017 07:31:26
|
DGAP-Ad hoc: PledPharma AB
DGAP-Ad-hoc: PledPharma AB Stockholm, 2017-11-20 07:30 CET (GLOBE NEWSWIRE) --
Under the terms of this agreement, PledPharma grants exclusive development and commercialization rights to PledOx(R) in the territories mentioned and Solasia will pay upfront, development, regulatory and sales milestones of up to ~USD 83 million (SEK 700 million)*. In addition, Solasia will pay industry standard royalty rates on sales applicable for a deal pertaining to an in-licensed asset in Phase III development. Solasia will also fully finance an expansion of the Phase III program to include Asian patients subject to regulatory consultations. The license agreement is initially focused on the use of PledOx(R) as prevention of chemotherapy induced peripheral neuropathy in colorectal cancer patients. The agreement with Solasia facilitates an expansion of the recently announced global Phase III-program for PledOx(R) with Asian patients, subject to regulatory consultations, aiming to gain sufficient documentation for regulatory approvals in the major Asian markets. In addition, a Phase I study in Japanese and Caucasian Healthy Volunteers with focus on safety, tolerability and pharmacokinetics will be conducted. Following potential regulatory approvals, Solasia will be responsible for the commercialization of PledOx(R) in Japan, China, Hong Kong, Macau, South Korea, and Taiwan. 'We are very excited to announce our partnership with Solasia - an ideal partner during the development, regulatory process and commercialization of PledOx in this very important region. The collaboration will ensure an optimized expansion of the Phase III program to include Asian patients, aiming at further realising the global commercial potential of our drug candidate,' said Nicklas Westerholm, Chief Executive Officer and President, PledPharma. 'We are convinced that PledOx, as a novel first in class therapy, will play an important role in fulfilling the significant unmet medical need of preventing chemotherapy induced peripheral neuropathy. Solasia is ideally equipped to support PledPharma during the remaining clinical development and local regulatory processes in Japan, and to effectively launch the product in key Asian markets,' said Yoshihiro Arai, President and Chief Executive Officer, Solasia. As PledPharma announced earlier in November, following interactions with the regulatory authorities, EMA and FDA, the company has finalized the design of the global Phase III program for the drug candidate PledOx(R). The Phase III studies are anticipated to be initiated at the end of 2017 with top line results expected during 2020. * The total value of upfront and milestone payments is up to JPY 9.3 billion. The amount given in USD and SEK is subject to exchange rate.
Invitation to corporate presentation
About PledOx(R)
About chemotherapy induced peripheral neuropathy (CIPN)
About Solasia
About PledPharma For further information, please contact:
Nicklas Westerholm, Chief Executive Officer, PledPharma AB
Rie Toyoda, Investor Relations, Solasia Pharma K.K.
This information is information that PledPharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07:30 CET on November 20, 2017 Click on, or paste the following link into your web browser, to view the associated documents https://cns.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=653705
20-Nov-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | PledPharma AB |
Sweden | |
ISIN: | SE0003815604 |
End of Announcement | DGAP News Service |
|
630719 20-Nov-2017 CET/CEST

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu PledPharma ABmehr Nachrichten
07:01 |
Ausblick: PledPharma AB stellt Zahlen zum jüngsten Quartal vor (finanzen.net) | |
11.02.25 |
Erste Schätzungen: PledPharma AB vermeldet Zahlen zum jüngsten Quartal (finanzen.net) | |
07.11.24 |
Ausblick: PledPharma AB öffnet die Bücher zum abgelaufenen Quartal (finanzen.net) | |
24.10.24 |
Erste Schätzungen: PledPharma AB stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net) |
Analysen zu PledPharma ABmehr Analysen
Aktien in diesem Artikel
PledPharma AB | 0,43 | 2,16% |
|